Immunic, Inc. Added to NASDAQ Biotechnology Index
December 14, 2020NEW YORK, December 14, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…BEAT-COV Initiative Requests Support for the Development and Production of New, Innovative COVID-19 Therapies (in German Only)
December 2, 2020Initiative BEAT-COV fordert Unterstützung für Entwicklung und Produktion neuer, innovativer COVID-19-Medikamente Deutschland, 02. Dezember 2020 – „Wir können lebenswichtige Medikamente zur…Immunic, Inc. to Participate in Investor Conferences in December
November 24, 2020NEW YORK, November 24, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…Immunic, Inc. Announces Formation of Scientific-Medical Advisory Board
November 17, 2020– Initial Appointments Include Internationally Recognized Experts: Fred D. Lublin, M.D.; Bruce E. Sands, M.D., M.S.; Jerrold R. Turner, M.D., Ph.D.…Immunic, Inc. to Participate in Investor and Scientific Conferences in November
November 10, 2020NEW YORK, November 10, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…Immunic, Inc. Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 5, 2020– Released Very Positive Phase 2 Data for IMU-838 in Relapsing-Remitting Multiple Sclerosis; Company to Submit End-of-Phase 2 Meeting Requests…Immunic, Inc. Announces 200 Patients Enrolled in Its Phase 2 CALVID-1 Trial of IMU-838 for the Treatment of Moderate COVID-19, Allowing for Main Phase 2 Efficacy Analysis to Proceed
November 2, 2020– Top-Line Data Expected in Q1 2021 – NEW YORK, November 2, 2020 – Immunic, Inc. (Nasdaq: IMUX),a clinical-stage biopharmaceutical company…EIB Provides Immunic With up to €24.5 Million to Support Ongoing Development of a Potential COVID-19 Therapy
October 20, 2020EIB Provides Immunic With up to €24.5 Million to Support Ongoing Development of a Potential COVID-19 Therapy Luxembourg, Gräfelfing, Germany…Immunic, Inc. to Participate in Scientific Conferences in October
September 29, 2020NEW YORK, September 29, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…Immunic, Inc. Announces Results From Interim Safety Analysis and Recruitment Update From Its Ongoing Phase 2 CALVID-1 Trial of IMU-838 in Patients With Moderate COVID-19
September 28, 2020NEW YORK, September 28, 2020 – Immunic, Inc. (Nasdaq: IMUX),a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies…
